secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0001140361-23-008076
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna enters exclusive license with Factor for patents; prior deal terminated
------------------------------------------------------------------------------

- Exclusive worldwide license under Factor's patents for human uses; term ends Nov 22, 2027, auto-renewed 2.5 years if Eterna receives $100M in sublicense fees.
- Eterna pays Factor 20% of sublicense fees before expiration, 30% during renewal; CEO Matthew Angel is co-founder/CEO of Factor's parent (related party).
- Prior license agreement (April 2021, amended Nov 2022) terminated and superseded by this new agreement on Feb 20, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036123008076/0001140361-23-008076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036123008076/brhc10048628_form8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-008076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer